The Foundation for Orthopaedics and Regenerative Medicine
This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.
Stem cell treatment has shown efficacy for PCOS in both human and animal studies. Complete resolution was seen of polycystic ovary syndrome (PCOS) in a young woman after a single intravenous injection of umbilical cord or placental derived mesenchymal stem cells (MSC). It is hypothesized that intravenous infusion of MSC can reduce or eliminate PCOS. Hormone levels and ultrasound will be checked 3,6 and 12 months after treatment.
Inclusion Criteria: • Ultrasound documented poly cystic ovary syndrome Exclusion Criteria: * Active infection * Active cancer * Chronic multisystem organ failure * Pregnancy * Clinically significant abnormalities on pre-treatment laboratory evaluation * Medical condition that would (based on the opinion of the investigator) compromise patient's safety * Continued drug abuse * Previous organ transplant * Hypersensitivity to sulfur * Inability to supply proper informed consent
Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.